Advertisement

Aprea Therapeutics, Inc. APRE

Set alert

Price alert · APRE

All alert types
0.48 USD -0.01 -1.82%

At close · Oct 30

0.48 0.00 0.00%

After hours · Oct 30, 4:00 PM ET

Bid
0.48 × 2
Ask
0.51 × 2
0.46 Day range 0.5214
0.449 52-week range 1.45
YTD
-43.19%
1 year
-66.58%
Open
0.4788
Prev close
0.4936
Mkt cap
6.10M
Vol
167.61K
Avg vol
308.29K
EPS
-0.95
P/E
0.00
Div yield
0.00%
More statistics
Low
0.46
High
0.5214
Forward P/E
-3.08
Beta
1.74
Short ratio
0.55
Inst. own
43.85%
Dividend
0.00
Ex-div date
Earnings
Aug 12, 2024
50-d avg
3.48
200-d avg
4.17
1y target
15.67

2Y chart

Chart tools
Interval

Events in this range
  • Nov 7, 2024Earnings: -0.64; estimate -0.75; surprise 14.67%
  • Nov 18, 2024Rating: HC Wainwright & Co. · Buy → Buy
  • Dec 17, 2024Rating: HC Wainwright & Co. · Buy → Buy
Signals (72)
NameDateAgo
RSI: OversoldOct 26, 20265 days ago
RSI: OversoldOct 8, 20263 weeks ago
SMA: BearishOct 1, 20261 month ago
SMA: BearishSep 9, 20261 month ago
MACD: Sell SignalSep 9, 20261 month ago
SMA: BullishSep 8, 20261 month ago
SMA: BearishSep 2, 20261 month ago
SMA: BullishSep 1, 20262 months ago
SMA: BearishAug 31, 20262 months ago
SMA: BullishAug 25, 20262 months ago
RSI: OverboughtAug 25, 20262 months ago
SMA: BullishAug 24, 20262 months ago
MACD: Buy SignalAug 6, 20262 months ago
MACD: Sell SignalJul 9, 20263 months ago
MACD: Buy SignalJun 22, 20264 months ago
SMA: BearishJun 1, 20265 months ago
MACD: Sell SignalMay 29, 20265 months ago
MACD: Buy SignalMay 22, 20265 months ago
SMA: BullishMay 20, 20265 months ago
SMA: BearishMay 19, 20265 months ago
MACD: Sell SignalMay 18, 20265 months ago
MACD: Buy SignalMay 8, 20265 months ago
SMA: BullishMay 1, 20266 months ago
SMA: BearishApr 30, 20266 months ago
MACD: Sell SignalApr 28, 20266 months ago
SMA: BullishApr 10, 20266 months ago
MACD: Buy SignalApr 9, 20266 months ago
SMA: BearishApr 1, 20267 months ago
SMA: BullishMar 31, 20267 months ago
MACD: Sell SignalMar 12, 20267 months ago
SMA: BearishMar 11, 20267 months ago
SMA: BullishFeb 25, 20268 months ago
MACD: Buy SignalFeb 18, 20268 months ago
RSI: OversoldJan 28, 20269 months ago
MACD: Sell SignalJan 26, 20269 months ago
RSI: OversoldDec 31, 202510 months ago
MACD: Buy SignalDec 19, 202510 months ago
RSI: OversoldDec 16, 202510 months ago
RSI: OversoldDec 9, 202510 months ago
MACD: Sell SignalDec 2, 202511 months ago
MACD: Buy SignalNov 26, 202511 months ago
MACD: Sell SignalOct 27, 20251 year ago
SMA: BearishOct 21, 20251 year ago
MACD: Buy SignalSep 29, 20251 year ago
MACD: Sell SignalSep 16, 20251 year ago
MACD: Buy SignalSep 8, 20251 year ago
SMA: BearishAug 6, 20251 year ago
SMA: BullishAug 5, 20251 year ago
SMA: BearishJul 31, 20251 year ago
MACD: Sell SignalJul 31, 20251 year ago
SMA: BullishJul 30, 20251 year ago
SMA: BearishJul 29, 20251 year ago
MACD: Buy SignalJul 22, 20251 year ago
MACD: Sell SignalJul 15, 20251 year ago
SMA: BearishJul 11, 20251 year ago
MACD: Buy SignalJul 8, 20251 year ago
SMA: BullishJul 3, 20251 year ago
SMA: BearishJun 27, 20251 year ago
SMA: BullishJun 25, 20251 year ago
SMA: BearishJun 20, 20251 year ago
MACD: Sell SignalJun 18, 20251 year ago
SMA: BullishJun 2, 20251 year ago
SMA: BearishMay 30, 20251 year ago
SMA: BullishMay 29, 20251 year ago
MACD: Buy SignalApr 16, 20251 year ago
MACD: Sell SignalApr 1, 20251 year ago
RSI: OversoldApr 1, 20251 year ago
MACD: Buy SignalMar 12, 20251 year ago
RSI: OversoldMar 3, 20251 year ago
RSI: OversoldFeb 21, 20251 year ago
SMA: BearishFeb 11, 20251 year ago
MACD: Sell SignalJan 29, 20251 year ago

Key statistics

Market cap
17.07M
Enterprise value
-5.20M
Trailing P/E
0.00
Forward P/E
-3.08
PEG ratio
0.00
Price / sales
13.38
Price / book
0.69
EPS (TTM)
-2.80
Beta
1.74
Dividend yield
0.00%
Payout ratio
0.00%
Profit margin
0.00%
Revenue (TTM)
1.28M
Revenue growth
124.90%
Free cash flow
-9.36M
Total cash
28.69M
Total debt
0
Return on equity
-50.11%
Shares outstanding
5.43M
Short % of float
0.38%
50-day average
3.48
200-day average
4.17

Analyst view

Consensus: buy

Buy
Price target (mean) 15.67 +3132.9% upside
Target (low)
11.00
Target (mean)
15.67
Target (high)
20.00
Ratings (0m) 3 3 buy · 0 hold · 0 sell
  • Strong buy2
  • Buy1
  • Hold0
  • Sell0
  • Strong sell0

Next earnings

Aug 12, 2024

Expected Aug 12, 2024. Consensus EPS estimate -0.57.

Earnings history

Financials — quick view

All financials
APRE Revenue — quarterly 0
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
APRE Net income — quarterly -3.59M
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
APRE EPS — quarterly -0.07
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026

Earnings

APRE recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Nov 7, 2024Sep 1, 2024-0.75-0.64+0.11+14.67%
Aug 12, 2024Jun 1, 2024-0.64-0.58+0.06+9.38%
Aug 12, 2024Jun 1, 2024-0.64———
May 14, 2024Mar 1, 2024-0.78———
May 14, 2024Mar 1, 2024-0.78-0.67+0.11+14.10%
Mar 26, 2024Dec 1, 2023-0.56-0.92-0.36-64.29%

Upgrades / downgrades

APRE analyst upgrades and downgrades
DateFirmActionFromTo
Dec 17, 2024HC Wainwright & Co.reitBuyBuy
Nov 18, 2024HC Wainwright & Co.reitBuyBuy
Oct 24, 2024HC Wainwright & Co.reitBuyBuy
Aug 13, 2024WedbushreitOutperformOutperform
Aug 12, 2024HC Wainwright & Co.reitBuyBuy
Jun 24, 2024HC Wainwright & Co.reitBuyBuy

About Aprea Therapeutics, Inc.

Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors. The company is also developing ATRN-1051 for the treatment of ovarian cancer; and APRE-DDRi for the treatment of advanced solid tumors. The company is headquartered in Doylestown, Pennsylvania.

Sector
Healthcare
Industry
Biotechnology
Country
United States
Website
aprea.com

News

Your note

Sign in to keep a note on APRE — it syncs with the Stock Master app.

Insider holders

APRE insider holders
InsiderRelationLatest transactionDateShares held
DUEY MARCDirectorSaleOct 17, 2024234,253
GILAD OREN PH.D.Chief Executive OfficerPurchaseOct 22, 2024335,195
GRISSINGER MICHAEL J.DirectorStock Award(Grant)Jun 19, 20241,844
HAMILL JOHN PChief Financial OfficerPurchaseOct 10, 202419,368
HENNEMAN JOHN BELL IIIDirectorStock Award(Grant)Jun 19, 20249,184
MIRZA NADEEM Q.OfficerStock Award(Grant)Apr 30, 20246,730

Institution ownership

APRE institution ownership
Holder% heldSharesValueReported
AIGH Capital Management LLC9.92%539,3001.69MSep 29, 2024
Sio Capital Management, LLC5.09%276,603868.53KSep 29, 2024
Sphera Funds Management Ltd.4.97%270,000847.80KSep 29, 2024
Nantahala Capital Management, LLC3.79%205,760646.09KSep 29, 2024
Vanguard Group Inc3.20%173,842545.86KSep 29, 2024
Stonepine Capital Management, LLC2.52%137,174430.73KSep 29, 2024

Fund ownership

APRE fund ownership
Holder% heldSharesValueReported
Vanguard Total Stock Market Index Fund2.67%145,280456.18KSep 29, 2024
Vanguard Extended Market Index Fund0.53%28,56289.68KSep 29, 2024
Fidelity Extended Market Index Fund0.47%25,27579.36KOct 30, 2024
Fidelity Total Market Index Fund0.13%7,19722.60KOct 30, 2024
Fidelity Series Total Market Index Fund0.11%5,96318.72KOct 30, 2024
Dimensional ETF Tr-Dimensional U.S. Targeted Value ETF0.09%5,08315.96KJul 30, 2024
Advertisement